Musunuri Shankar sold $54K of OCGN (indirect holdings)

Ocugen reported Q3 2026 earnings with a loss of 6 cents per share (excluding derivative liability), matching estimates. Revenue rose 11.4% YoY to $1.95M, beating estimates. Shares rose 17.4% post-results. R&D expenses increased 12.1% YoY. The company expects funds to support operations into 2028. Ocugen is advancing its gene therapy pipeline with three BLA submissions targeted by 2028.

Ocugen Inc (OCGN) reported Q3 2026 earnings, highlighting progress in three gene therapy programs. OCU-400 Phase 3 trial expects 50% response rate, with top-line data due Q1 2027. OCU-410 trials for geographic atrophy and Stargardt disease are on track, with data readouts expected in 2027. The company has $84.6M cash runway into 2028. Licensing deals for OCU-400 in the Middle East and South Korea were announced, with potential milestone payments and royalties.

Ocugen reported Q3 2026 progress, with all three late-stage gene therapy programs in phase III. OCU400 for retinitis pigmentosa completed enrollment, with top-line data expected in Q1 2027. The company secured a $4M upfront license deal for the Middle East and North Africa. Financials showed $84.6M in cash and a $0.01 net loss per share, down from $0.07 in 2025. Ocugen aims to file three BLAs by 2028.

Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ocugen Provides Business Update with Third Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET · Received Provisional Approval and Priority Designation for OCU400 in The Bahamas o Executed agreement with local partner Global Alliance for

Ocugen (OCGN) licensed MENA rights for OCU400 to Roots Pharmaceutical, receiving up to $259M in milestones and a 22% royalty. Roots will handle regulatory filings and commercialization, while Ocugen supplies the product. The agreement aims to expand OCU400's market reach.

Ocugen (OCGN) licensed OCU400, a gene therapy for retinitis pigmentosa, to Roots Pharmaceutical for the MENA region. The deal includes up to $255 million in milestone payments and 22% royalties. Ocugen will manufacture and supply the therapy. Phase 3 trial data is expected in Q1 2027. OCGN stock closed at $0.88, up 2.78% in pre-market trading.